Table 1.
Description of the patients and treatments received for the first primary cancer before the second primary cancer
| Cytotoxics only |
Cytotoxics and immunotherapy |
Immunotherapy only |
Neither cytotoxics nor immunotherapy |
All patients |
||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
n = 16 997 |
n = 1131 |
n = 32 |
n = 28 669 |
N = 46 829 |
||||||
| n | % | n | % | n | % | n | % | n | % | |
| Sex | ||||||||||
| Female | 9657 | (56.8%) | 426 | (37.7%) | 14 | (43.8%) | 16 628 | (58.0%) | 26 725 | (57.1%) |
| Male | 7340 | (43.2%) | 705 | (62.3%) | 18 | (56.3%) | 12 041 | (42.0%) | 20 104 | (42.9%) |
| Age of cancer 1 | ||||||||||
| n | 16 997 | 1131 | 32 | 28 669 | 46 829 | |||||
| Mean (SE) | 57.7 (18.6) | 59.6 (12.6) | 50.8 (19.0) | 57.2 (18.8) | 57.5 (18.6) | |||||
| Median (min; max) | 60.9 (0; 100) | 60.9 (0; 90) | 54.9 (10; 77) | 60.0 (0; 115) | 60.4 (0; 115) | |||||
| Q1-Q3 | 48.1-70.4 | 52.0-67.8 | 43.8-65.1 | 46.1-70.5 | 47.1-70.4 | |||||
| Classes of age for first cancera | ||||||||||
| <30 | 1436 | (8.4%) | 24 | (2.1%) | 5 | (15.6%) | 2597 | (9.1%) | 4062 | (8.7%) |
| 30-60 | 6737 | (39.6%) | 509 | (45.0%) | 14 | (43.8%) | 11 717 | (40.9%) | 18 977 | (40.5%) |
| >60 | 8824 | (51.9%) | 598 | (52.9%) | 13 | (40.6%) | 14 355 | (50.1%) | 23 790 | (50.8%) |
| Cancer sites | ||||||||||
| Breast | 4809 | (28.3%) | 33 | (2.9%) | 1 | (3.1%) | 6857 | (23.9%) | 11700 | (25.0%) |
| Lung | 2125 | (12.5%) | 486 | (43.0%) | 11 | (34.4%) | 2084 | (7.3%) | 4706 | (10.0%) |
| Head & neck | 929 | (5.5%) | 167 | (14.8%) | 5 | (15.6%) | 2286 | (8.0%) | 3387 | (7.2%) |
| Gynecological | 1105 | (6.5%) | 62 | (5.5%) | 0 | (0.0%) | 1967 | (6.9%) | 3134 | (6.7%) |
| Digestive | 1445 | (8.5%) | 53 | (4.7%) | 1 | (3.1%) | 1498 | (5.2%) | 2997 | (6.4%) |
| Connective tissue | 646 | (3.8%) | 19 | (1.7%) | 0 | (0.0%) | 2253 | (7.9%) | 2918 | (6.2%) |
| Colorectal | 1099 | (6.5%) | 30 | (2.7%) | 1 | (3.1%) | 1545 | (5.4%) | 2675 | (5.7%) |
| Prostate | 643 | (3.8%) | 11 | (1.0%) | 0 | (0.0%) | 1732 | (6.0%) | 2386 | (5.1%) |
| Urothelial | 434 | (2.6%) | 142 | (12.6%) | 1 | (3.1%) | 837 | (2.9%) | 1414 | (3.0%) |
| Thyroid | 220 | (1.3%) | 7 | (0.6%) | 0 | (0.0%) | 1106 | (3.9%) | 1333 | (2.8%) |
| Skin cancer | 149 | (0.9%) | 57 | (5.0%) | 0 | (0.0%) | 713 | (2.5%) | 919 | (2.0%) |
| Others | 3393 | (20.0%) | 64 | (5.7%) | 12 | (37.5%) | 5791 | (20.2%) | 9260 | (19.8%) |
| Metastatic at diagnosis | ||||||||||
| No | 10 199 | (60.0%) | 492 | (43.5%) | 31 | (96.9%) | 28 669 | (100.0%) | 39 391 | (84.1%) |
| Yes | 6798 | (40.0%) | 639 | (56.5%) | 1 | (3.1%) | 0 | (0.0%) | 7438 | (15.9%) |
| Second primary cancer | ||||||||||
| No | 16 560 | (97.4%) | 1125 | (99.5%) | 31 | (96.9%) | 27 283 | (95.2%) | 44 999 | (96.1%) |
| Yes | 437 | (2.6%) | 6 | (0.5%) | 1 | (3.1%) | 1386 | (4.8%) | 1830 | (3.9%) |
| Histotypes (second cancer) | ||||||||||
| Head & neck | 47 | (0.3%) | 0 | (0.0%) | 0 | (0.0%) | 185 | (0.6%) | 232 | (0.5%) |
| Sarcoma | 43 | (0.3%) | 0 | (0.0%) | 0 | (0.0%) | 153 | (0.5%) | 196 | (0.4%) |
| Lung | 40 | (0.2%) | 0 | (0.0%) | 0 | (0.0%) | 140 | (0.5%) | 180 | (0.4%) |
| Breast | 54 | (0.3%) | 0 | (0.0%) | 0 | (0.0%) | 104 | (0.4%) | 158 | (0.3%) |
| Digestiveb | 36 | (0.2%) | 0 | (0.0%) | 1 | (3.1%) | 99 | (0.3%) | 136 | (0.3%) |
| Skin | 30 | (0.2%) | 1 | (0.1%) | 0 | (0.0%) | 83 | (0.3%) | 114 | (0.2%) |
| Colorectal | 22 | (0.1%) | 3 | (0.3%) | 0 | (0.0%) | 69 | (0.2%) | 94 | (0.2%) |
| Gynecological | 19 | (0.1%) | 0 | (0.0%) | 0 | (0.0%) | 70 | (0.2%) | 89 | (0.2%) |
| Urothelial | 12 | (0.1%) | 0 | (0.0%) | 0 | (0.0%) | 53 | (0.2%) | 65 | (0.1%) |
| Thyroid | 11 | (0.1%) | 0 | (0.0%) | 0 | (0.0%) | 38 | (0.1%) | 49 | (0.1%) |
| Prostate | 4 | (0.0%) | 0 | (0.0%) | 0 | (0.0%) | 31 | (0.1%) | 35 | (0.1%) |
| Other | 119 | (0.7%) | 2 | (0.2%) | 0 | (0.0%) | 361 | (1.3%) | 482 | (1.0%) |
SE, standard error.
a
Adults and children treated in the Centre Léon Bérard were all included in this analysis.
b
Digestive: non-colorectal carcinoma (CRC).